Departmento de Radiología, Neurorradiología Intervencionista, Hospital Clínic, Barcelona, Spain.
Departmento de Radiología, Neurorradiología Intervencionista, Hospital Clínic, Barcelona, Spain.
Radiologia (Engl Ed). 2022 Mar-Apr;64(2):103-109. doi: 10.1016/j.rxeng.2020.04.009.
To determine the safety and efficacy of angioplasty with a retrievable stent in treating vasospasm secondary to subarachnoid hemorrhage (SAH) due to an aneurysm.
We retrospectively analyzed prospectively collected data from consecutive patients undergoing endovascular angioplasty with a retrievable stent to treat vasospasm related to SAH due to an aneurysm in four neurointerventional radiology departments between January 2018 and July 2019. We included patients aged >18 years with vasospasm >50% of the internal carotid artery (ICA), anterior cerebral artery (ACA), and / or middle cerebral artery (MCA) secondary to SAH due to an aneurysm treated with endovascular angioplasty with a retrievable stent. The variables used to measure safety were complications of the procedure and clinical complications. The variables used to measure radiological efficacy were improvement in the degree of stenosis after endovascular treatment and improvement or normalization of cerebral circulation time CTT).
We included 16 angioplasty procedures with retrievable stents in 13 patients, in which 33 arterial segments were treated (10 ICA, 15 MCA, and 8 ACA). We observed no complications of the procedure in any patients and no clinical complications in patients who were not intubated. All but one of the patients who had delayed CTT at the beginning of the procedure showed improvements in CTT. The mean improvement in the degree of stenosis was 18% ± 11.65% in the ICA, 30.67% ± 18.45% in the MCA, and 28.38% ± 15.49% in the ACA. No statistically significant associations were observed between endovascular treatment variables and the degree of improvement in stenosis.
Angioplasty with a retrievable stent is a safe and efficacious treatment for vasospasm secondary to SAH due to an aneurysm, improving CTT and stenosis.
评估血管内球囊成形术联合可回收支架治疗颅内动脉瘤性蛛网膜下腔出血(SAH)后血管痉挛的安全性和疗效。
我们对 2018 年 1 月至 2019 年 7 月期间 4 个神经介入放射学部门连续接受血管内球囊成形术联合可回收支架治疗颅内动脉瘤性 SAH 后血管痉挛的患者进行了前瞻性数据回顾性分析。纳入标准为年龄>18 岁,因颅内动脉瘤性 SAH 导致颈内动脉(ICA)、大脑前动脉(ACA)和/或大脑中动脉(MCA)血管痉挛>50%,接受血管内球囊成形术联合可回收支架治疗的患者。安全性评估的变量包括手术并发症和临床并发症。影像学疗效评估的变量包括血管内治疗后狭窄程度的改善和脑循环时间(CTT)的改善或正常化。
我们纳入了 13 例患者的 16 例血管内球囊成形术联合可回收支架治疗,共治疗了 33 个动脉节段(10 个 ICA、15 个 MCA 和 8 个 ACA)。我们观察到所有患者均无手术相关并发症,未插管患者也无临床并发症。在开始治疗时 CTT 延迟的患者中,除 1 例外,所有患者的 CTT 均有所改善。ICA 的狭窄程度平均改善 18%±11.65%,MCA 的狭窄程度平均改善 30.67%±18.45%,ACA 的狭窄程度平均改善 28.38%±15.49%。未发现血管内治疗变量与狭窄程度改善之间存在统计学显著相关性。
血管内球囊成形术联合可回收支架治疗颅内动脉瘤性蛛网膜下腔出血后血管痉挛安全有效,可改善 CTT 和狭窄程度。